Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.

• In the current study, we investigate the activation of antiapoptotic signaling pathways in response to proteasome inhibitor treatment in pancreatic cancer and evaluate the use of concomitant inhibition of these pathways to augment proteasome inhibitor treatment responses.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Adenocarcinoma

drug therapy

metabolism

Animals

Antibodies

Monoclonal

administration & dosage

Antibodies

Monoclonal

Humanized

Antineoplastic Combined Chemotherapy Protocols

therapeutic use

Apoptosis

drug effects

physiology

Blotting

Western

Boronic Acids

administration & dosage

Cell Line

Tumor

Deoxycytidine

administration & dosage

analogs & derivatives

Female

Humans

Lactones

administration & dosage

Mice

Mice

Nude

Pancreatic Neoplasms

drug therapy

metabolism

Phosphatidylinositol 3-Kinases

drug effects

metabolism

Protease Inhibitors

therapeutic use

Proteasome Inhibitors

Pyrazines

administration & dosage

Pyrroles

administration & dosage

Quinazolines

administration & dosage

Receptor

Epidermal Growth Factor

drug effects

metabolism

Signal Transduction

drug effects

physiology

Xenograft Model Antitumor Assays

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)